Stokes Capital Advisors LLC Reduces Holdings in Abbott Laboratories $ABT

Key Points

• Stokes Capital Advisors LLC has reduced its holdings in Abbott Laboratories by 4.0% in the second quarter, now owning 47,302 shares valued at approximately $6.43 million.
• Multiple hedge funds have adjusted their stakes in Abbott, with Brighton Jones LLC increasing its holdings by 10.1% to own 51,719 shares valued at $5.85 million.
• Abbott Laboratories reported a net margin of 32.43% and revenue of $11.14 billion for the quarter, exceeding analysts' expectations with a year-over-year revenue growth of 7.4%.

Stokes Capital Advisors LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,302 shares of the healthcare product maker's stock after selling 1,993 shares during the quarter. Stokes Capital Advisors LLC's holdings in Abbott Laboratories were worth $6,434,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in ABT. Brighton Jones LLC increased its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG grew its holdings in shares of Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after buying an additional 2,774 shares in the last quarter. Vident Advisory LLC raised its position in shares of Abbott Laboratories by 30.2% in the fourth quarter. Vident Advisory LLC now owns 34,899 shares of the healthcare product maker's stock valued at $3,948,000 after buying an additional 8,098 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $5,997,000. Finally, Williams Jones Wealth Management LLC. boosted its position in Abbott Laboratories by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 177,705 shares of the healthcare product maker's stock worth $20,100,000 after acquiring an additional 3,393 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Mizuho raised their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 16th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and raised their target price for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Morgan Stanley raised their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Raymond James Financial lowered their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Trading Up 1.1%

NYSE ABT opened at $132.76 on Wednesday. The company's fifty day simple moving average is $130.35 and its 200-day simple moving average is $131.22. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market cap of $231.06 billion, a P/E ratio of 16.64, a PEG ratio of 2.49 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.